Xcout Intel
Nuclidium AG
Nuclidium is a precision oncology company headquartered in Basel, Switzerland. It specializes in developing next-generation copper radiotheranostics to provide personalized treatment options for cancer patients at various stages.
Subscribe to see Nuclidium AG’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Nuclidium AG at a glance
Nuclidium AG is a biotechnology company headquartered in Switzerland. It has raised at least $119.9M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $30.9M in May 2026. Xcout tracks 22 named people at Nuclidium AG, including Max Azaham (Chief Financial Officer).
Nuclidium AG leadership
- Max AzahamChief Financial Officer
- Dr. Thomas ReinerChief Scientific Officer
- Dr. Leila Jaafar-ThielChief Executive Officer
- Leila JaafarCEO and Co-Founder
- Prof. Dr. Gustav von Schulthess (MD, PhD)Medical Advisor & Co-Founder
- Denise LeeVP Clinical Operations
16 more named people on record for Nuclidium AG, with roles, board committees and tenure — see the full roster →
Nuclidium AG funding rounds
At least $119.9M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $30.9M | 10 named | |
| Series B | $89M | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Nuclidium AG competitors
A few of Nuclidium AG's closest competitors — see the full list of competitors and alternatives →
ITM Isotope Technologies Munich SE develops and supplies targeted radiopharmaceuticals, including diagnostics and therapeutics, for cancer care. The company focuses on precision oncology treatments such as radioligand therapies for hard-to-treat tumors and produces medical radioisotopes like Lutetium-177 and Actinium-225 to serve patients globally.
Ratio Therapeutics is a clinical-stage pharmaceutical company headquartered in Boston, Massachusetts. The company employs a suite of innovative technologies for the discovery and early clinical development of targeted radiopharmaceuticals.
Actithera, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on delivering targeted radioligand cancer therapies.
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that develops targeted, bespoke molecules using peptide engineering and iterative design to treat cancer patients with precision. The company advances a portfolio of radiotherapeutics utilizing optimized binders, linkers, chelators, and radioisotopes for solid tumors.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
ARTBIO is a biotechnology company developing targeted alpha-particle radioligand therapies for cancer, including treatments intended to selectively deliver radioactive payloads to tumor cells. Its work is aimed at serving oncology patients and healthcare providers treating solid tumors.
Get Nuclidium AG's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Nuclidium AG in Xcout Intel
- 22 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access